NCT05915208Recruiting
Histiocytic Disorder Follow-up Study
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 25 May 2023
- Start date
- 1 Sept 2022
- Primary completion date
- Jul 2027
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Childhood cancers
- NCT number
- NCT05915208
What you commit to
- Study type: Observational
- Planned participants: 6000
- From 1 Sept 2022 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- diagnosis of histiocytic disorder at any age
- Langerhans cell histiocytosis,
- Erdheim-Chester disease,
- Rosai-Dorfman disease,
- Xanthogranuloma,
- Mixed histiocytosis
- Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
- Hemophagocytic lymphohistiocytosis
Age in the registry: 0 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.